Concord Medical Services Holdings Limited Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 8 of 8 Posts
Week In Review: Concord Medical Raises $240 Million For China Radiology Services
Article By: ChinaBio® Today Saturday, April 7, 2018 4:30 PM EDT
Concord Medical Services announced that CICC Capital led an investment of between $238 million and $286 million in Concord’s subsidiary Beijing Meizhong Jiahe Hospital Management. The investors will hold 37.5% to 41.9% of Meizhong Jiahe's equity.
In this article: CCM, LLY
Week In Review: China's Sanpower Pays $820M For Provenge, A Prostate Immunotherapy
Article By: ChinaBio® Today Saturday, January 14, 2017 12:58 PM EDT
Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world's first immunotherapy, from Valeant Pharma.
In this article: CCM, VRX, KITE, ABBV, MRK
Week In Review: New Deals Fund China Life Science Innovation
Article By: ChinaBio® Today Saturday, September 3, 2016 1:30 PM EDT
Beijing Allcure Medical Technology, a radiology oncology startup developing big data/cloud computing applications, raised $27 million in an A+ funding round.
In this article: CCM, SVA
Week In Review: China Bridge Capital Announces $1.5 Billion Precision Medicine Fund
Article By: ChinaBio® Today Saturday, July 16, 2016 12:24 PM EDT
China Bridge Capital, a Beijing financial services firm, invested $45 million in iCarbonX, the big data/AI healthcare start-up that raised $155 million in a Series A at a $1 billion valuation earlier this year.
In this article: CCM, CRXM
Week In Review: Xinbang Pharma Acquires Chinese Peptide Co. For $323 Million
Article By: ChinaBio® Today Saturday, May 9, 2015 3:54 PM EDT
Bayer AG announced that the CFDA has approved Xarelto (rivaroxaban), a once-daily oral anticoagulant, for two new anti-clotting indications: strokes and deep vein thrombosis.
In this article: BAX, MACK, BAYN, CCM, QGEN, AZN, PVCT
Week In Review: ZAI Lab To Develop BMS Liver Cancer Drug In China
Article By: ChinaBio® Today Sunday, March 29, 2015 5:28 AM EDT
ZAI Lab of Shanghai in-licensed China rights to a liver cancer drug candidate from Bristol-Myers Squibb. Brivanib is an oral kinase inhibitor that is in Phase III trials for oncology indications.
In this article: BMY, CCM, WX, AZN, CASI
Look Back To Look Ahead In 2015
Video By: Zacks Investment Research Monday, January 19, 2015 7:25 PM EDT
Equity Strategist John Blank reviews how 2014 market events will shape this year (video).
In this video: BSFT, CCM
Market Strategy: Look Back To Look Forward
Article By: Zacks Investment Research Monday, January 12, 2015 7:09 PM EDT
Naming the most attractive sectors, and which ones are lame.
In this article: CCM, BSFT, BRK-B
1 to 8 of 8 Posts